For patients living with pulmonary arterial hypertension (PAH), the window between diagnosis and critical heart failure can be unpredictably short. New research from the University of Alberta has identified a genetic variant that may allow clinicians to predict which patients are at the highest risk for rapid decline, potentially shifting the timing of life-saving interventions like heart transplants.
PAH is a rare and aggressive condition where the walls of the lung arteries thicken and overgrow. This creates a physical obstruction that forces the right chambers of the heart to work harder to pump blood through the lungs. Over time, the heart muscle exhausts itself, leading to right-sided heart failure.
The stakes are exceptionally high: roughly 50 percent of patients die within five years of diagnosis. This prognosis is comparable to metastatic breast cancer, reflecting the severity of the disease’s progression.
Predicting the ‘Decompensation’ of the Heart
Until now, doctors have struggled to explain why some patients maintain stability for years while others experience a rapid “decompensation”—a sudden failure of the heart’s ability to function. In a study published in the American Heart Association’s journal Circulation, a team led by Dr. Evangelos Michelakis found a specific genetic variant present in about 30 percent of patients. This variant serves as a marker for those predisposed to early right-heart failure.
The findings, developed through collaborations with Laval University and Duke University, were reinforced by testing both animal models and human heart tissue. The data suggests that the genetic marker, combined with levels of systemic inflammation, creates a high-risk profile for rapid deterioration.
This inflammatory link is particularly relevant for patients who also battle autoimmune conditions, such as lupus or scleroderma, which often coexist with PAH and may accelerate the heart’s decline.
Clinical Context: The Treatment Gap
Current PAH drug therapies are often prohibitively expensive and, while they may manage symptoms, they frequently fail to reverse the underlying disease or significantly prolong life. Because many patients deteriorate rapidly, they often become too sick to qualify for or survive a heart transplant—the only truly effective intervention.
From Genetic Markers to Clinical Action
The immediate value of this discovery lies in its accessibility. Dr. Michelakis notes that this genetic variant can be detected via a simple mouth swab, while inflammation can be tracked through standard blood tests and medical history. This suggests a future where a “risk score” could be established at the moment of diagnosis.
If validated in larger populations, this approach could change the standard of care in three specific ways:
- Intensified Monitoring: High-risk patients would receive more frequent follow-ups to catch signs of failure earlier.
- Aggressive Therapy: Clinicians might opt for more intensive drug regimens for those genetically predisposed to rapid decline.
- Earlier Transplant Referral: By identifying high-risk patients sooner, surgeons could initiate the transplant process before the patient becomes too unstable for the procedure.
While these results are promising, they remain in the validation phase. The researchers must now reproduce these findings across larger, more diverse patient groups to ensure the test’s accuracy before it can be integrated into routine medical practice.
The research was supported by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada and the University Hospital Foundation.
For families and patients, the hope is that the “guessing game” of disease progression will be replaced by a precision-medicine approach that prioritizes the most vulnerable patients for the most urgent care.
Quick Analysis: Key Takeaways
- The Discovery: A genetic variant found in 30% of PAH patients predicts early right-heart failure.
- The Risk Factor: Systemic inflammation (often linked to lupus or scleroderma) further accelerates heart decompensation.
- The Goal: Use simple swabs and blood tests to trigger earlier transplant referrals and more aggressive care.
- The Caveat: Results must be replicated in larger populations before becoming a clinical standard.
How might the ability to predict disease progression change the way patients and families plan for long-term care in rare disease scenarios?





